Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Sarepta Therapeutics, Inc.SRPT · Entity 4426 | EVP, General Counsel | June 22, 2020 | June 23, 2020 |
| Solid Biosciences Inc.SLDB · Entity 4915 | Chief Operating Officer | January 29, 2026 | April 21, 2026 |
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | SVP & Chief Legal Officer | February 02, 2012 | February 06, 2012 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Sarepta Therapeutics, Inc.
Report date June 22, 2020 · Filed June 23, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 31,871 |
Ending reported balance
After 2020-06-22 transaction · row 8
8 source rows · reconciled sequenceRow 1 · 2020-06-22 · Exercise / conversion · Acquired 1,280 · Balance 33,151 F1: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Row 2 · 2020-06-22 · Exercise / conversion · Acquired 1,858 · Balance 35,009 F1: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Row 3 · 2020-06-22 · Exercise / conversion · Acquired 56,984 · Balance 91,993 F1: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Row 4 · 2020-06-22 · Exercise / conversion · Acquired 45,000 · Balance 136,993 F1: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Row 5 · 2020-06-22 · Sale · Disposed 6,009 · Balance 130,984 F1: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. F2: The shares were sold in transactions at prices ranging from $168.04 to $169.0399, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 6 · 2020-06-22 · Sale · Disposed 8,086 · Balance 122,898 F1: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. F3: The shares were sold in transactions at prices ranging from $169.09 to $170.0899, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 7 · 2020-06-22 · Sale · Disposed 35,757 · Balance 87,141 F1: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. F4: The shares were sold in transactions at prices ranging from $170.09 to $171.0899, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Row 8 · 2020-06-22 · Sale · Disposed 55,270 · Balance 31,871 F1: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. F5: The shares were sold in transactions at prices ranging from $171.09 to $172.0899, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.71 · Expires 2026-02-28 | Direct | 0 |
Reported balance
After 2020-06-22 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2020-06-22 · Exercise / conversion · Disposed 1,280 · Balance 0 F1: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.71 · Expires 2026-02-28 | Direct | 0 |
Reported balance
After 2020-06-22 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2020-06-22 · Exercise / conversion · Disposed 1,858 · Balance 0 F1: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.85 · Expires 2022-11-05 | Direct | 0 |
Reported balance
After 2020-06-22 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2020-06-22 · Exercise / conversion · Disposed 56,984 · Balance 0 F1: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.03 · Expires 2024-02-28 | Direct | 7,708 |
Reported balance
After 2020-06-22 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2020-06-22 · Exercise / conversion · Disposed 45,000 · Balance 7,708 F1: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction.
F2: The shares were sold in transactions at prices ranging from $168.04 to $169.0399, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
F3: The shares were sold in transactions at prices ranging from $169.09 to $170.0899, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
F4: The shares were sold in transactions at prices ranging from $170.09 to $171.0899, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
F5: The shares were sold in transactions at prices ranging from $171.09 to $172.0899, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein.
Solid Biosciences Inc.
Report date January 29, 2026 · Filed April 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 79,341 |
Reported balance
After 2026-01-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-29 · Grant · Acquired 79,341 · Balance 79,341 F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs"). F2: Performance stock units ("PSUs") were granted on June 11, 2024, and provide for the vesting of 25% of the target number of underlying RSUs granted upon the achievement of each of four independent performance milestones predetermined by the Board ("Performance Milestones"). The Performance Milestones are tied to the achievement of certain business objectives, as certified by the Board on specified evaluation dates, and are non-market and non-financial in nature. The performance criteria specified for the second Performance Milestone was determined by the Board to be met on January 29, 2026, and the shares related to such Performance Milestone will vest subject to the grantee's continued service with the Company on the Evaluation Date, which is anticipated to occur in the first quarter of 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs").
F2: Performance stock units ("PSUs") were granted on June 11, 2024, and provide for the vesting of 25% of the target number of underlying RSUs granted upon the achievement of each of four independent performance milestones predetermined by the Board ("Performance Milestones"). The Performance Milestones are tied to the achievement of certain business objectives, as certified by the Board on specified evaluation dates, and are non-market and non-financial in nature. The performance criteria specified for the second Performance Milestone was determined by the Board to be met on January 29, 2026, and the shares related to such Performance Milestone will vest subject to the grantee's continued service with the Company on the Evaluation Date, which is anticipated to occur in the first quarter of 2027.
VERTEX PHARMACEUTICALS INC / MA
Report date February 02, 2012 · Filed February 06, 2012
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 19,437 |
Reported balance
After 2012-02-02 transaction · row 1
1 source rowRow 1 · 2012-02-02 · Grant · Acquired 10,166 · Balance 19,437 F1: Stock grant under 2006 Stock and Option Plan, vesting on 2/2/2016, subject to (i) earlier acceleration of 50% of shares upon (A) reaching specified aggregate product and royalty sales levels or (B) completing enrollment of a pivotal trial in two distinct disease indications other than HCV and cystic fibrosis and (ii) earlier acceleration of 50% of shares upon receiving filing confirmation for an NDA for an all-oral regimen for the treatment of HCV infection. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $37.86 · Expires 2022-02-01 | Direct | 68,750 |
Reported balance
After 2012-02-02 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2012-02-02 · Grant · Acquired 68,750 · Balance 68,750 F2: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/02/2012. |
| Common StockSEC Table I · non-derivative | Indirect401(k) | 266 |
Reported balance
Holding disclosure · report date 2012-02-02 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 266 |
Filing footnotes · ownership attribution and instrument terms
F1: Stock grant under 2006 Stock and Option Plan, vesting on 2/2/2016, subject to (i) earlier acceleration of 50% of shares upon (A) reaching specified aggregate product and royalty sales levels or (B) completing enrollment of a pivotal trial in two distinct disease indications other than HCV and cystic fibrosis and (ii) earlier acceleration of 50% of shares upon receiving filing confirmation for an NDA for an all-oral regimen for the treatment of HCV infection.
F2: Right to buy under 2006 Stock and Option Plan, vesting in 16 quarterly installments from 02/02/2012.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 18, 2026 Filed Feb 19, 2026 02:31 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | SaleCommon Stock | 7,469 | $5.82 | $43,494.23 |
DisclosureSEC source: 0001193125-26-057863 · ownership.xml · nonDerivative · entry 2 Howton David T · CIK 0001529297 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,077 F2 · shares: This sale was made to cover withholding taxes following the vesting of the previously granted RSUs pursuant to a durable automatic sales instruction letter adopted by Mr. Howton on August 16, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Mr. Howton. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.23 to $6.14, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form. Read SEC document |
| February 13, 2026 Filed Feb 19, 2026 02:31 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionRestricted Stock Units · Derivative | 14,687 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-057863 · ownership.xml · derivative · entry 3 Howton David T · CIK 0001529297 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,376 Underlying: Common Stock · 14,687 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs"). F4 · derivative.exercise_date: The RSUs were granted on February 13, 2024 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary. F4 · derivative.expiration_date: The RSUs were granted on February 13, 2024 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary. Read SEC document |
| February 13, 2026 Filed Feb 19, 2026 02:31 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionCommon Stock | 14,687 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-057863 · ownership.xml · nonDerivative · entry 1 Howton David T · CIK 0001529297 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 112,546 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs"). Read SEC document |
| February 04, 2026 Filed Feb 6, 2026 23:05 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | SaleCommon Stock | 18,894 | $6.44 | $121,713.26 |
DisclosureSEC source: 0001193125-26-041523 · ownership.xml · nonDerivative · entry 1 Howton David T · CIK 0001529297 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 97,859 F1 · shares: This sale was made to cover withholding taxes following the vesting of previously granted restricted stock units pursuant to a durable automatic sale instruction letter adopted by Mr. Howton on August 16, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Mr. Howton. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.28 to $6.60, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form. Read SEC document |
| February 02, 2026 Filed Feb 3, 2026 01:12 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | SaleCommon Stock | 37,771 | $6.44 | $243,128.15 |
DisclosureSEC source: 0001193125-26-034080 · ownership.xml · nonDerivative · entry 3 Howton David T · CIK 0001529297 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 116,753 F3 · shares: This sale was made to cover withholding taxes following the vesting of previously granted PSUs pursuant to a durable automatic sale instruction letter adopted by Mr. Howton on August 16, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Mr. Howton. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.295 to $6.580, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (4) to this Form. Read SEC document |
| January 31, 2026 Filed Feb 3, 2026 01:12 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionRestricted Stock Units · Derivative | 42,275 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-034080 · ownership.xml · derivative · entry 7 Howton David T · CIK 0001529297 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 126,825 Underlying: Common Stock · 42,275 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted stock unit ("RSUs") converts to common stock on a one-for-one basis. F8 · derivative.exercise_date: On January 31, 2025 (the "2025 Grant Date"), the reporting person was granted 169,100 RSUs, with 25% of the original number of shares vesting on each anniversary of the 2025 Grant Date until the fourth such anniversary. F8 · derivative.expiration_date: On January 31, 2025 (the "2025 Grant Date"), the reporting person was granted 169,100 RSUs, with 25% of the original number of shares vesting on each anniversary of the 2025 Grant Date until the fourth such anniversary. Read SEC document |
| January 31, 2026 Filed Feb 3, 2026 01:12 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionCommon Stock | 42,275 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-034080 · ownership.xml · nonDerivative · entry 2 Howton David T · CIK 0001529297 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 154,254 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each restricted stock unit ("RSUs") converts to common stock on a one-for-one basis. Read SEC document |
| January 29, 2026 Filed Feb 3, 2026 01:12 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantRestricted Stock Units · Derivative | 105,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-034080 · ownership.xml · derivative · entry 6 Howton David T · CIK 0001529297 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,100 Underlying: Common Stock · 105,100 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSUs") converts to common stock on a one-for-one basis. F7 · derivative.exercise_date: The RSUs were granted on the 2026 Grant Date and vest over four years, with 25% of the original number of shares vesting on each anniversary of the 2026 Grant Date until the fourth such anniversary. F7 · derivative.expiration_date: The RSUs were granted on the 2026 Grant Date and vest over four years, with 25% of the original number of shares vesting on each anniversary of the 2026 Grant Date until the fourth such anniversary. Read SEC document |
| January 29, 2026 Filed Feb 3, 2026 01:12 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantEmployee Stock Option (Right to Buy) · Derivative | 210,200 | $0.00 Strike: $6.60 | $0.00 |
DisclosureSEC source: 0001193125-26-034080 · ownership.xml · derivative · entry 5 Howton David T · CIK 0001529297 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 210,200 Underlying: Common Stock · 210,200 shares Expires 2036-01-29 F6 · derivative.exercise_date: This option was granted on the 2026 Grant Date and vests over four years, with 25% of the original number of shares vesting on the first anniversary of the 2026 Grant Date and 2.0833% of the original number of shares monthly thereafter until the fourth such anniversary. Read SEC document |
| January 29, 2026 Filed Feb 3, 2026 01:12 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionPerformance Stock Units · Derivative | 79,341 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-034080 · ownership.xml · derivative · entry 4 Howton David T · CIK 0001529297 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 79,341 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance stock unit ("PSUs") converts to common stock on a one-for-one basis. F5 · derivative.exercise_date: The PSUs were granted on June 11, 2024 and provide for the vesting of 25% of the target number of underlying RSUs granted upon the achievement of each of four independent performance milestones predetermined by the Board ("Performance Milestones"), subject to the grantee's continued service with the Company (the "Approval Conditions"). The Performance Milestones are tied to the achievement of certain business objectives, as certified by the Board on specified evaluation dates, and are non-market and non-financial in nature. The performance criteria specified for the first Performance Milestone was determined to be met on January 29, 2026 (the "2026 Grant Date") resulting in the vesting of the PSUs as to 25% of the underlying shares. F5 · derivative.expiration_date: The PSUs were granted on June 11, 2024 and provide for the vesting of 25% of the target number of underlying RSUs granted upon the achievement of each of four independent performance milestones predetermined by the Board ("Performance Milestones"), subject to the grantee's continued service with the Company (the "Approval Conditions"). The Performance Milestones are tied to the achievement of certain business objectives, as certified by the Board on specified evaluation dates, and are non-market and non-financial in nature. The performance criteria specified for the first Performance Milestone was determined to be met on January 29, 2026 (the "2026 Grant Date") resulting in the vesting of the PSUs as to 25% of the underlying shares. Read SEC document |
| January 29, 2026 Filed Feb 3, 2026 01:12 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionCommon Stock | 79,341 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-034080 · ownership.xml · nonDerivative · entry 1 Howton David T · CIK 0001529297 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 112,249 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each performance stock unit ("PSUs") converts to common stock on a one-for-one basis. Read SEC document |
| January 29, 2026 Filed Apr 21, 2026 20:05 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantRestricted Stock Units · Derivative | 79,341 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-166736 · ownership.xml · derivative · entry 1 Howton David T · CIK 0001529297 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 79,341 Underlying: Common Stock · 79,341 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs"). F2 · derivative.exercise_date: Performance stock units ("PSUs") were granted on June 11, 2024, and provide for the vesting of 25% of the target number of underlying RSUs granted upon the achievement of each of four independent performance milestones predetermined by the Board ("Performance Milestones"). The Performance Milestones are tied to the achievement of certain business objectives, as certified by the Board on specified evaluation dates, and are non-market and non-financial in nature. The performance criteria specified for the second Performance Milestone was determined by the Board to be met on January 29, 2026, and the shares related to such Performance Milestone will vest subject to the grantee's continued service with the Company on the Evaluation Date, which is anticipated to occur in the first quarter of 2027. F2 · derivative.expiration_date: Performance stock units ("PSUs") were granted on June 11, 2024, and provide for the vesting of 25% of the target number of underlying RSUs granted upon the achievement of each of four independent performance milestones predetermined by the Board ("Performance Milestones"). The Performance Milestones are tied to the achievement of certain business objectives, as certified by the Board on specified evaluation dates, and are non-market and non-financial in nature. The performance criteria specified for the second Performance Milestone was determined by the Board to be met on January 29, 2026, and the shares related to such Performance Milestone will vest subject to the grantee's continued service with the Company on the Evaluation Date, which is anticipated to occur in the first quarter of 2027. Read SEC document |
| December 03, 2025 Filed Dec 4, 2025 21:22 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | SaleCommon Stock | 4,932 | $5.11 | $25,202.52 |
DisclosureSEC source: 0001193125-25-308118 · ownership.xml · nonDerivative · entry 2 Howton David T · CIK 0001529297 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,908 F2 · shares: This sale was made to cover withholding taxes following the vesting of the previously granted RSUs pursuant to a durable automatic sales instruction letter adopted by Mr. Howton on August 16, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Mr. Howton. Read SEC document |
| December 02, 2025 Filed Dec 4, 2025 21:22 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionRestricted Stock Units · Derivative | 13,051 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-308118 · ownership.xml · derivative · entry 3 Howton David T · CIK 0001529297 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,052 Underlying: Common Stock · 13,051 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs"). F3 · derivative.exercise_date: The RSUs were granted on December 2, 2022 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary. F3 · derivative.expiration_date: The RSUs were granted on December 2, 2022 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary. Read SEC document |
| December 02, 2025 Filed Dec 4, 2025 21:22 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionCommon Stock | 13,051 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-25-308118 · ownership.xml · nonDerivative · entry 1 Howton David T · CIK 0001529297 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,840 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs"). Read SEC document |
| August 14, 2025 Filed Aug 18, 2025 20:16 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantRestricted Stock Units · Derivative | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-109736 · ownership.xml · derivative · entry 2 Howton David T · CIK 0001529297 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock (the "RSUs"). F1 · derivative.exercise_date: The RSUs (as defined in footnote 2) together with this option were granted on August 14, 2025 (the "Grant Date") and vest over four years, with 50% of the original number of shares vesting on the second anniversary of the Grant Date and 25% of the original number of shares annually thereafter until the fourth such anniversary. F1 · derivative.expiration_date: The RSUs (as defined in footnote 2) together with this option were granted on August 14, 2025 (the "Grant Date") and vest over four years, with 50% of the original number of shares vesting on the second anniversary of the Grant Date and 25% of the original number of shares annually thereafter until the fourth such anniversary. Read SEC document |
| August 14, 2025 Filed Aug 18, 2025 20:16 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantEmployee Stock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $6.17 | $0.00 |
DisclosureSEC source: 0000950170-25-109736 · ownership.xml · derivative · entry 1 Howton David T · CIK 0001529297 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2035-08-14 F1 · derivative.exercise_date: The RSUs (as defined in footnote 2) together with this option were granted on August 14, 2025 (the "Grant Date") and vest over four years, with 50% of the original number of shares vesting on the second anniversary of the Grant Date and 25% of the original number of shares annually thereafter until the fourth such anniversary. Read SEC document |
| February 14, 2025 Filed Feb 18, 2025 21:05 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | SaleCommon Stock | 5,561 | $3.96 | $22,021.56 |
DisclosureSEC source: 0000950170-25-022196 · ownership.xml · nonDerivative · entry 2 Howton David T · CIK 0001529297 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,789 F2 · shares: This sale was made to cover withholding taxes following the vesting of the previously granted RSUs pursuant to a durable automatic sales instruction letter adopted by Mr. Howton on August 16, 2024 effecting the sell-to-cover election. The sale does not represent a discretionary trade by Mr. Howton. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 21:05 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionRestricted Stock Units · Derivative | 14,687 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-022196 · ownership.xml · derivative · entry 3 Howton David T · CIK 0001529297 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,063 Underlying: Common Stock · 14,687 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs"). F3 · derivative.exercise_date: The RSUs were granted on February 13, 2024 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary. F3 · derivative.expiration_date: The RSUs were granted on February 13, 2024 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary. Read SEC document |
| February 13, 2025 Filed Feb 18, 2025 21:05 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionCommon Stock | 14,687 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-022196 · ownership.xml · nonDerivative · entry 1 Howton David T · CIK 0001529297 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,350 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs"). Read SEC document |
| January 31, 2025 Filed Feb 11, 2025 21:38 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantRestricted Stock Units · Derivative | 169,100 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-017962 · ownership.xml · derivative · entry 1 Howton David T · CIK 0001529297 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 169,100 Underlying: Common Stock · 169,100 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock (the "RSUs"). F2 · derivative.exercise_date: The RSUs were granted on the January 31, 2025 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary. F2 · derivative.expiration_date: The RSUs were granted on the January 31, 2025 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary. Read SEC document |
| December 03, 2024 Filed Dec 4, 2024 22:04 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | SaleCommon Stock | 5,072 | $5.60 | $28,396.10 |
DisclosureSEC source: 0000950170-24-133340 · ownership.xml · nonDerivative · entry 2 Howton David T · CIK 0001529297 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,663 F2 · shares: This sale was made to cover withholding taxes following the vesting of the previously granted RSUs. The sale does not represent a discretionary trade made by Mr. Howton. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 22:04 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionRestricted Stock Units · Derivative | 13,051 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-133340 · ownership.xml · derivative · entry 3 Howton David T · CIK 0001529297 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,103 Underlying: Common Stock · 13,051 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs"). F3 · derivative.exercise_date: The RSUs were granted on December 2, 2022 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary. F3 · derivative.expiration_date: The RSUs were granted on December 2, 2022 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 22:04 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionCommon Stock | 13,051 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-133340 · ownership.xml · nonDerivative · entry 1 Howton David T · CIK 0001529297 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,735 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs"). Read SEC document |
| February 13, 2024 Filed Feb 16, 2024 16:28 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantRestricted Stock Units · Derivative | 58,750 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-016193 · ownership.xml · derivative · entry 2 Howton David T · CIK 0001529297 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,750 Underlying: Common Stock · 58,750 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock (the "RSUs"). F3 · derivative.exercise_date: The RSUs were granted on the Grant Date and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary. F3 · derivative.expiration_date: The RSUs were granted on the Grant Date and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary. Read SEC document |
| February 13, 2024 Filed Feb 16, 2024 16:28 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantEmployee Stock Option (Right to Buy) · Derivative | 117,500 | $0.00 Strike: $7.85 | $0.00 |
DisclosureSEC source: 0000950170-24-016193 · ownership.xml · derivative · entry 1 Howton David T · CIK 0001529297 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,500 Underlying: Common Stock · 117,500 shares Expires 2034-02-13 F1 · derivative.exercise_date: This option was granted on February 13, 2024 (the "Grant Date") and vests over four years, with 25% of the original number of shares vesting on the first anniversary of the Grant Date and 2.0833% of the original number of shares monthly thereafter until the fourth such anniversary. Read SEC document |
| December 04, 2023 Filed Dec 5, 2023 19:32 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | SaleCommon Stock | 5,367 | $2.78 | $14,920.26 |
DisclosureSEC source: 0000950170-23-068067 · ownership.xml · nonDerivative · entry 2 Howton David T · CIK 0001529297 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,684 F2 · shares: This sale was made to cover withholding taxes following the vesting of the previously granted RSUs. The shares were sold pursuant to a written instruction under Rule 10b5-1(c)(1). Read SEC document |
| December 02, 2023 Filed Dec 5, 2023 19:32 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionRestricted Stock Units · Derivative | 13,051 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-068067 · ownership.xml · derivative · entry 3 Howton David T · CIK 0001529297 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,154 Underlying: Common Stock · 13,051 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs"). F3 · derivative.exercise_date: The RSUs were granted on December 2, 2022 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary. F3 · derivative.expiration_date: The RSUs were granted on December 2, 2022 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary. Read SEC document |
| December 02, 2023 Filed Dec 5, 2023 19:32 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | Exercise / conversionCommon Stock | 13,051 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-23-068067 · ownership.xml · nonDerivative · entry 1 Howton David T · CIK 0001529297 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,051 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock (the "RSUs"). Read SEC document |
| December 02, 2022 Filed Dec 5, 2022 22:50 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantRestricted Stock Units · Derivative | 52,205 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-037686 · doc4.xml · derivative · entry 2 Howton David T · CIK 0001529297 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,205 Underlying: Common Stock · 52,205 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock (the "RSUs"). F3 · derivative.exercise_date: The RSUs were granted on the Grant Date and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary. F3 · derivative.expiration_date: The RSUs were granted on the Grant Date and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary. Read SEC document |
| December 02, 2022 Filed Dec 5, 2022 22:50 UTC | Solid Biosciences Inc. SLDB · Entity 4915 | GrantStock Option (Right to Buy) · Derivative | 104,410 | $0.00 Strike: $6.77 | $0.00 |
DisclosureSEC source: 0000899243-22-037686 · doc4.xml · derivative · entry 1 Howton David T · CIK 0001529297 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,410 Underlying: Common Stock · 104,410 shares Expires 2032-12-02 F1 · derivative.exercise_date: This option was granted on December 2, 2022 (the "Grant Date") and vests over four years, with 25% of the original number of shares vesting on the first anniversary of the Grant Date and 2.0833% of the original number of shares on the first day of each calendar month thereafter until the fourth such anniversary. Read SEC document |
| June 22, 2020 Filed Jun 23, 2020 01:17 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock option (right to buy) · Derivative | 45,000 | $0.00 Strike: $29.03 | $0.00 |
DisclosureSEC source: 0001209191-20-038339 · doc4.xml · derivative · entry 12 Howton David T · CIK 0001529297 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,708 Underlying: Common Stock · 45,000 shares Expires 2024-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| June 22, 2020 Filed Jun 23, 2020 01:17 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock option (right to buy) · Derivative | 56,984 | $0.00 Strike: $23.85 | $0.00 |
DisclosureSEC source: 0001209191-20-038339 · doc4.xml · derivative · entry 11 Howton David T · CIK 0001529297 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 56,984 shares Expires 2022-11-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| June 22, 2020 Filed Jun 23, 2020 01:17 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock option (right to buy) · Derivative | 1,858 | $0.00 Strike: $13.71 | $0.00 |
DisclosureSEC source: 0001209191-20-038339 · doc4.xml · derivative · entry 10 Howton David T · CIK 0001529297 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,858 shares Expires 2026-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| June 22, 2020 Filed Jun 23, 2020 01:17 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock option (right to buy) · Derivative | 1,280 | $0.00 Strike: $13.71 | $0.00 |
DisclosureSEC source: 0001209191-20-038339 · doc4.xml · derivative · entry 9 Howton David T · CIK 0001529297 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,280 shares Expires 2026-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| June 22, 2020 Filed Jun 23, 2020 01:17 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 55,270 | $171.50 | $9,478,805.00 |
DisclosureSEC source: 0001209191-20-038339 · doc4.xml · nonDerivative · entry 8 Howton David T · CIK 0001529297 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,871 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. F5 · price: The shares were sold in transactions at prices ranging from $171.09 to $172.0899, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| June 22, 2020 Filed Jun 23, 2020 01:17 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 35,757 | $170.59 | $6,099,786.63 |
DisclosureSEC source: 0001209191-20-038339 · doc4.xml · nonDerivative · entry 7 Howton David T · CIK 0001529297 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,141 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. F4 · price: The shares were sold in transactions at prices ranging from $170.09 to $171.0899, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| June 22, 2020 Filed Jun 23, 2020 01:17 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 8,086 | $169.56 | $1,371,062.16 |
DisclosureSEC source: 0001209191-20-038339 · doc4.xml · nonDerivative · entry 6 Howton David T · CIK 0001529297 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,898 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. F3 · price: The shares were sold in transactions at prices ranging from $169.09 to $170.0899, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| June 22, 2020 Filed Jun 23, 2020 01:17 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 6,009 | $168.61 | $1,013,177.49 |
DisclosureSEC source: 0001209191-20-038339 · doc4.xml · nonDerivative · entry 5 Howton David T · CIK 0001529297 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,984 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. F2 · price: The shares were sold in transactions at prices ranging from $168.04 to $169.0399, inclusive. The reporting person undertakes to provide to Sarepta Therapeutics, Inc., any security holder of Sarepta Therapeutics, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| June 22, 2020 Filed Jun 23, 2020 01:17 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 45,000 | $29.03 | $1,306,350.00 |
DisclosureSEC source: 0001209191-20-038339 · doc4.xml · nonDerivative · entry 4 Howton David T · CIK 0001529297 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,993 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| June 22, 2020 Filed Jun 23, 2020 01:17 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 56,984 | $23.85 | $1,359,068.40 |
DisclosureSEC source: 0001209191-20-038339 · doc4.xml · nonDerivative · entry 3 Howton David T · CIK 0001529297 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,993 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| June 22, 2020 Filed Jun 23, 2020 01:17 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 1,858 | $13.71 | $25,473.18 |
DisclosureSEC source: 0001209191-20-038339 · doc4.xml · nonDerivative · entry 2 Howton David T · CIK 0001529297 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,009 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| June 22, 2020 Filed Jun 23, 2020 01:17 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 1,280 | $13.71 | $17,548.80 |
DisclosureSEC source: 0001209191-20-038339 · doc4.xml · nonDerivative · entry 1 Howton David T · CIK 0001529297 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,151 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| February 28, 2020 Filed Feb 29, 2020 01:01 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantStock option (right to buy) · Derivative | 37,500 | $0.00 Strike: $114.47 | $0.00 |
DisclosureSEC source: 0001209191-20-014224 · doc4.xml · derivative · entry 2 Howton David T · CIK 0001529297 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires 2030-02-28 F2 · derivative.exercise_date: 25% of the option granted vests and is exercisable on the first anniversary of the date of grant and 1/48th of the total granted option will vest and become exercisable on each monthly anniversary thereafter, such that the option will be fully vested and exercisable on the fourth anniversary of the date of grant. Read SEC document |
| February 28, 2020 Filed Feb 29, 2020 01:01 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | GrantCommon Stock | 6,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-014224 · doc4.xml · nonDerivative · entry 1 Howton David T · CIK 0001529297 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,871 F1 · shares: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. 25% of the shares of common stock underlying each RSU will vest and become exercisable on the first anniversary of the grant date, and additional 25% will vest and become exercisable on each anniversary of the Grant Date thereafter, such that the RSUs will be fully vested and exercisable on the fourth anniversary of the grant date. F1 · price: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. 25% of the shares of common stock underlying each RSU will vest and become exercisable on the first anniversary of the grant date, and additional 25% will vest and become exercisable on each anniversary of the Grant Date thereafter, such that the RSUs will be fully vested and exercisable on the fourth anniversary of the grant date. Read SEC document |
| December 13, 2019 Filed Dec 18, 2019 01:01 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock option (right to buy) · Derivative | 59,421 | $0.00 Strike: $23.85 | $0.00 |
DisclosureSEC source: 0001209191-19-061049 · doc4.xml · derivative · entry 5 Howton David T · CIK 0001529297 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,984 Underlying: Common Stock · 59,421 shares Expires 2022-11-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| December 13, 2019 Filed Dec 18, 2019 01:01 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionStock option (right to buy) · Derivative | 18,579 | $0.00 Strike: $13.90 | $0.00 |
DisclosureSEC source: 0001209191-19-061049 · doc4.xml · derivative · entry 4 Howton David T · CIK 0001529297 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 18,579 shares Expires 2025-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| December 13, 2019 Filed Dec 18, 2019 01:01 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | SaleCommon Stock | 78,000 | $125.50 | $9,789,000.00 |
DisclosureSEC source: 0001209191-19-061049 · doc4.xml · nonDerivative · entry 3 Howton David T · CIK 0001529297 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,171 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| December 13, 2019 Filed Dec 18, 2019 01:01 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 59,421 | $23.85 | $1,417,190.85 |
DisclosureSEC source: 0001209191-19-061049 · doc4.xml · nonDerivative · entry 2 Howton David T · CIK 0001529297 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,171 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
| December 13, 2019 Filed Dec 18, 2019 01:01 UTC | Sarepta Therapeutics, Inc. SRPT · Entity 4426 | Exercise / conversionCommon Stock | 18,579 | $13.90 | $258,248.10 |
DisclosureSEC source: 0001209191-19-061049 · doc4.xml · nonDerivative · entry 1 Howton David T · CIK 0001529297 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 Plan adopted by the reporting person. Accordingly, the reporting person had no discretion with regards to the timing of the transaction. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.